Skip to main content
. 2020 Nov 6;99(45):e23169. doi: 10.1097/MD.0000000000023169

Table 1.

Demographic and clinical characteristics of patients (N = 118).

Clinical characteristics N (%)
Male sex 52 (44)
Age (yr); median (IQR) 1.7 (1.1–2.8)
Underlying diseases
 Biliary atresia 93 (78.8)
 Acute liver failure 7 (5.9)
 Allagile syndrome 4 (3.4)
 Other causes of cirrhosis 14 (11.8)
PELD score; median (IQR) 19 (16–23)
Previous abdominal surgery before LT 62 (52.5)
Donor
 Living Donor 113 (95.8)
 Cadaveric Donor 5 (4.2)
Antibiotic exposure within 3 mo before LT 63 (53.4)
Operation time (h); median (IQR) 11.1 (10.1–12.5)
Cold ischemic time (min); median (IQR) 72 (52–92)
Intraoperative complications
 Massive bleeding 84 (84)
 Bowel injury 6 (6)
 Adrenal gland injury 3 (3)
 Vascular injury 5 (5)
 Biliary injury 2 (2)
Hospital stay; median (IQR) 48 (34–65)
 <1 mo 20
 1–3 mo 80
 >3 mo 18
Length of ICU stay (d); median (IQR) 8 (6–14)
Duration of endotracheal intubation (d); median (IQR) 3 (2–7)
Duration of urinary catheter (d); median (IQR) 5 (3–6)
Duration of central venous catheter (d); median (IQR) 12 (8–17)
Duration of abdominal drain (d); median (IQR) 27 (20–37)
Early postoperative complications
 Bile leak 27 (33)
 Hepatic artery stenosis/thrombosis 18 (21.9)
 Hepatic vein stenosis/thrombosis 18 (21.9)
 Portal vein stenosis/thrombosis 19 (23.2)
Sites of infection
 Intra-abdominal infection 46 (46.4)
 Bloodstream infection 23 (23.2)
 Urinary tract infection 11 (11.1)
 Pneumonia 16 (16.2)
CMV reactivation 37 (31.4)
EBV reactivation 5 (4.2)
Acute graft rejection 21 (17.8)
Postoperative surgical intervention (ie, liver biopsy, abdominal drain insertion, PTBD insertion, dilate hepatic vein) 35 (29.6)
Re-operation 58 (49.1)
Death 8 (6.7)